NCT01280526已完成1 期
A Phase IB/II Study of Escalating Doses of Romidepsin (Istodax®) in Association With CHOP (Ro-CHOP) in the Treatment of Peripheral T-Cell Lymphomas
The Lymphoma Academic Research Organisation8 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2011年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 37
- 试验地点
- 8
- 主要终点
- Incidence of Dose Limiting Toxicities
研究概览
简要总结
This study is an open label, multicenter study with two phases:
- A dose escalation phase of Romidepsin administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)administered every 3 weeks for 8 cycles in patients with T-cell lymphoma.
- An expansion phase in order to assess the safety and the efficacy of the association of the recommended dose of Romidepsin associated with CHOP in a population of patients with T-cell lymphoma.
详细描述
The primary objective of the study is to determine the feasibility of the combination and the recommended dose (RD) of Romidepsin when administered in association with CHOP in a population of patients with newly diagnosed Peripheral T-cell lymphoma (PTCL) as measured by the toxicities during treatment.
Secondary objectives:
- To assess the safety of the association Romidepsin and CHOP,
- To assess the efficacy of the association of Romidepsin and CHOP: response rate and complete response rate, progression-free survival, response duration and overall survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically confirmed Peripheral T-cell Lymphoma (PTCL), not previously treated ; all subtypes may be included except HTLV-1-related T-cell lymphoma, cutaneous T-cell lymphoma (mycosis fungoid and Sézary syndrome), and ALK+ PTCL,
- •Ann Arbor stages II - IV
- •Aged from 18 to 80 years,
- •ECOG performance status 0, 1 or 2,
- •Signed informed consent,
- •Negative pregnancy test for females of childbearing potential (FCBP),
- •FCBP using an effective method of birth control (i.e. hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) for the treatment period and for 1 month thereafter; Males using an effective method of birth control for the treatment period and 3 months thereafter,
- •Life expectancy of ≥ 90 days (3 months)
排除标准
- •Other types of lymphomas, e.g. B-cell lymphoma
- •Ann Arbor stage I
- •Previous treatment for PTCL with immunotherapy or chemotherapy except for short-term corticosteroids before inclusion
- •Previous radiotherapy for PTCL except if localized to one lymph node area
- •Central nervous system - meningeal involvement
- •Contraindication to any drug contained in the chemotherapy regimen
- •HIV infection, active hepatitis B or C
- •Any serious active disease or co-morbid medical condition (according to investigator's decision)
- •Any of the following laboratory abnormalities
- •Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5 x 109/L),
- •Platelet count < 100,000/mm3 (100 x 109/L), or 75,000 if bone marrow is involved,
- •Serum SGOT/AST or SGPT/ALT ≥ 5.0 x upper limit of normal (ULN),
- •Serum total bilirubin > 2.0 mg/dL (34 µmol/L), except in case of hemolytic anemia,
- •Low K+ (inferior to low normal level) and low Mg+ (inferior to low normal level)levels, except if corrected before beginning the chemotherapy,
- •Use of oral contraceptive and contraceptive patches,
- •Calculated creatinine clearance (Cockcroft-Gault formula) of < 50 mL /min,
- •Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥ 3 years,
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form,
- •Left Ventricular Ejection Fraction < 45% (calculated by echocardiographic or scintigraphic methods),
- •Patients with congenital long QT syndrome, history of significant cardiovascular disease and/or taking drugs leading to significant QT prolongation,
- •Corrected QT interval > 480 msec (using the fridericia formula)
- •Use of any standard or experimental anti-cancer drug therapy within 28 days of the initiation (Day 1) of study drug ,
- •Pregnant or lactating females or women of childbearing potential not will-ing to use an adequate method of birth control for the duration of the study.
研究组 & 干预措施
Romidepsin dose 10mg/m²
Experimental
Romidepsin dose 10mg/m²
干预措施: Romidepsin and CHOP (Drug)
Romidepsin dose 12mg/m²
Experimental
Romidepsin dose 12mg/m²
干预措施: Romidepsin and CHOP (Drug)
Romidepsin dose 14mg/m²
Experimental
Romidepsin dose 14mg/m²
干预措施: Romidepsin and CHOP (Drug)
Romidepsin dose 8mg/m²
Experimental
Romidepsin dose 8mg/m²
干预措施: Romidepsin and CHOP (Drug)
结局指标
主要结局
Incidence of Dose Limiting Toxicities
时间窗: 42 days
次要结局
- Safety of association Romidepsin-CHOP(from the date of informed consent signature to 90 days after the last drug administration)
- Progression-free survival (PFS)(from the date of inclusion to the date of first documentated disease progression, relapse or death from any cause)
- Complete Response Rate(CR) at the end of treatment(30 days after the end of treatment)
- Duration of Response(from the date of first documentation of a response to the date of first documented evidence of progression/relapse or death from any cause)
- Overall Response at the end of treatment(30 days after the end of treatment)
- Overall Survival (OS)(from the date of inclusion to the date of first documentated disease progression, relapse or death from any cause)
研究者
研究点 (8)
Loading locations...
相似试验
终止
1 期
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple MyelomaNeoplasmsCancerNCT02082977GlaxoSmithKline41
终止
2 期
Trial of Romidepsin and Bortezomib for Multiple MyelomaMultiple MyelomaNCT00765102Celgene32
终止
1 期
APG-1387 Plus Chemotherapy in Advanced Pancreatic AdenocarcinomaAdvanced Pancreatic CancerNCT04643405Ascentage Pharma Group Inc.21
终止
1 期
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaNCT01602315Novartis Pharmaceuticals179
已完成
2 期
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell LymphomaPeripheral T-cell LymphomaNCT00426764Celgene131